Form 4: Cabaletta Bio Executive Granted Stock Options

Arun Das, Chief Business Officer of Cabaletta Bio, Inc., was granted stock options for 115,000 shares on March 3, 2025.

Summary

• Arun Das, the Chief Business Officer of Cabaletta Bio, Inc., filed a Form 4 on March 4, 2025.
• The filing reports a transaction that occurred on March 3, 2025, where Das was granted stock options to purchase 115,000 shares of Cabaletta Bio's common stock at an exercise price of $1.67 per share.
• The options vest 25% on March 3, 2026, and the remainder vests in twelve substantially equal quarterly installments thereafter, contingent upon continued service.
• The options expire on March 2, 2035.

Sentiment

Score: 7

Explanation: The granting of stock options is generally a positive sign, indicating confidence in the company's future and aligning executive interests with shareholders. However, it also represents potential future dilution.

Positives

• The granting of stock options aligns the executive's interests with those of the shareholders, incentivizing performance and company growth.

Future Outlook

The vesting schedule suggests a long-term commitment from the executive to the company's success.

Industry Context

Stock options are a common form of executive compensation in the biotechnology industry, used to attract and retain talent and align their interests with shareholders.

Comparison to Industry Standards

• Stock option grants are a standard component of compensation packages for executives in biotech companies like Cabaletta Bio.
• The vesting schedule, with a cliff vesting period followed by quarterly installments, is also typical in the industry, similar to practices at companies like Juno Therapeutics (acquired by Celgene) and Kite Pharma (acquired by Gilead).

Stakeholder Impact

• Shareholders may experience potential dilution upon exercise of the stock options.
• Employees may view the grant as a positive sign of the company's commitment to its leadership.

Key Dates